NCT04534309 (ASPIRE) is a NA clinical trial of Written Weight Loss Material in Breast Cancer, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

Who is sponsoring NCT04534309?

NCT04534309 is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

What drugs are being tested in NCT04534309?

Interventions in NCT04534309: Written Weight Loss Material, Weight Loss App, Behavioral Lifestyle Weight Loss Intervention (Coaching).

What condition does NCT04534309 study?

NCT04534309 studies Breast Cancer, Prostate Cancer, Melanoma (Skin), Endometrial Cancer, Gallbladder Cancer, Rectal Cancer, Kidney Cancer, Bladder Cancer.

Is NCT04534309 still recruiting?

NCT04534309 is currently completed. Last updated 10 October 2023.

Last reviewed 2023-10-10 · How we verify

NCT04534309: ASPIRE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Behavioral Weight Loss Program for Cancer Survivors in Maryland

Completed NA Last updated 10 October 2023

What this trial tests

NA trial testing Written Weight Loss Material in Breast Cancer in 340 participants. Completed in 30 June 2023.

Timeline

22 September 2020

Primary endpoint
15 December 2022

30 June 2023

Quick facts

Lead sponsor	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	prevention
Enrollment	340
Start date	22 September 2020
Primary completion	15 December 2022
Estimated completion	30 June 2023
Sites	1 location across United States

Drugs / interventions tested

Written Weight Loss Material
Weight Loss App
Behavioral Lifestyle Weight Loss Intervention (Coaching)

Conditions studied

Breast Cancer — all drugs for Breast Cancer →
Prostate Cancer — all drugs for Prostate Cancer →
Melanoma (Skin) — all drugs for Melanoma (Skin) →
Endometrial Cancer — all drugs for Endometrial Cancer →

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins — full company profile →

Who can join

18 and older, any sex, with Breast Cancer or Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Behavioral Weight Loss for Overweight and Obese Cancer Survivors in Maryland: A Demonstration Project

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

A Narrative Review of the Role of Diet and Lifestyle Factors in the Development and Prevention of Endometrial Cancer.
Yasin HK, Taylor AH, Ayakannu T. · · 2021 · cited 41× · PMID 33946913 · DOI 10.3390/cancers13092149
Randomized trial of two artificial intelligence coaching interventions to increase physical activity in cancer survivors.
Hassoon A, Baig Y, Naiman DQ, Celentano DD, et al · · 2021 · cited 36× · PMID 34887491 · DOI 10.1038/s41746-021-00539-9
Behavioral Weight Loss Programs for Cancer Survivors Throughout Maryland: Protocol for a Pragmatic Trial and Participant Characteristics.
Jerome GJ, Appel LJ, Bunyard L, Dalcin AT, et al · · 2024 · PMID 38865181 · DOI 10.2196/54126

Verify or expand the search:

Other recruiting trials for Breast Cancer

Currently open trials in the same condition.

NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting

Other Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins trials

Trials by the same sponsor.

NCT07424222 — Ruxolitinib for Immune Effector Cell Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (RISE) · Phase 1 · not yet recruiting
NCT06210854 — Assessing Administration of pBI-11 Via Electroporation for the Treatment of Patients With HPV16/18+ · Phase 2 · not yet recruiting
NCT07360119 — Total Pancreatectomy With Islet Autotransplantation (TPIAT) for High-Risk Patients With Pancreatic Tumors · NA · not yet recruiting
NCT07140315 — DK222 Study at Hopkins · Phase 1 · recruiting
NCT07071155 — Momelotinib in Combination With Hypomethylating Agent for Chronic Phase Myelodysplastic Syndromes/Myeloproliferative Ove · EARLY_PHASE1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04534309 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Last refreshed: 10 October 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04534309.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing